List view / Grid view

Eli Lilly & Company

 

news

FDA approves linagliptin tablets for the treatment of type 2 diabetes

3 May 2011 | By OgilvyHealthPR

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…